| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Estrogen receptor (ER) - estrogen-like activity.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Segetalin B, a cyclic pentapeptide from Vaccaria segetalis, possesses estrogen-like activity. The compound's estrogen-like activity suggests it may interact with estrogen receptors and modulate estrogen-responsive genes. The peptide has also been reported to have anti-inflammatory, antioxidant, and potential neuroactive effects. Its compact cyclic structure contributes to enhanced stability and resistance to enzymatic degradation, making it a useful molecule in natural product and peptide research.
|
| ln Vivo |
In vivo studies on Segetalin B are limited, as the compound is primarily used as a research tool for in vitro investigations of its biological activities. The compound's estrogen-like activity suggests potential applications in studying estrogen receptor signaling and in the development of phytoestrogen-based therapies. The compound's anti-inflammatory and antioxidant activities also suggest potential for further evaluation in models of inflammatory and oxidative stress-related diseases. Further studies are needed to assess the compound's pharmacokinetic properties, oral bioavailability, and efficacy in animal models.
|
| Enzyme Assay |
For estrogen-like activity studies, cell-based assays are performed using cells expressing estrogen receptors (ERα or ERβ), such as MCF-7 breast cancer cells. Cells are treated with Segetalin B at various concentrations, and estrogen receptor activation is assessed by measuring the expression of estrogen-responsive genes (e.g., pS2, progesterone receptor) by qRT-PCR or by using luciferase reporter assays. Cell proliferation assays are performed to assess the compound's estrogenic or anti-estrogenic effects. For anti-inflammatory activity, macrophage cell lines are treated with Segetalin B and stimulated with LPS, and cytokine production is measured by ELISA.
|
| Cell Assay |
Cellular assays for Segetalin B typically involve culturing estrogen receptor-expressing cell lines such as MCF-7 cells and treating them with the compound at various concentrations. Estrogen receptor activation is assessed by measuring cell proliferation (using MTT or CellTiter-Glo assays), expression of estrogen-responsive genes (by qRT-PCR), or by using reporter gene assays. For anti-inflammatory studies, macrophages are treated with the compound and stimulated with LPS, and cytokine production (TNF-α, IL-1β, IL-6) is measured by ELISA. Antioxidant activity is assessed by measuring intracellular ROS levels using fluorescent probes. Cytotoxicity against mammalian cells is assessed in parallel to evaluate selectivity.
|
| Animal Protocol |
In vivo efficacy of Segetalin B is evaluated in animal models relevant to its biological activities. For estrogen-like activity studies, ovariectomized rat or mouse models are used to assess the compound's ability to mimic estrogen effects on the uterus, bone, and other tissues. For anti-inflammatory studies, animal models of inflammation such as carrageenan-induced paw edema are used. For antioxidant studies, models of oxidative stress are used. The compound's ability to modulate estrogen receptor signaling, reduce inflammation, or protect against oxidative damage is assessed. Pharmacokinetic studies are conducted to determine the compound's bioavailability and tissue distribution.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Segetalin B have been studied in the context of its use as a natural product. The compound is a cyclic pentapeptide with a molecular weight of 484.55. As a peptide, Segetalin B is expected to have limited oral bioavailability due to degradation in the gastrointestinal tract. The compound's cyclic structure contributes to enhanced stability and resistance to enzymatic degradation compared to linear peptides. Key PK parameters including half-life, clearance, and bioavailability are determined using LC-MS/MS analysis of plasma and tissue samples. The compound's ability to reach target tissues is important for its efficacy in vivo.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation of Segetalin B is limited, as the compound is primarily studied as a natural product from Vaccaria segetalis, a plant used in traditional Chinese medicine. The compound's natural origin and traditional use suggest a potential favorable safety profile, though comprehensive toxicology data may be limited. Standard toxicology assessments for pharmaceutical applications would include in vitro cytotoxicity assays, acute and repeated-dose toxicity studies, and genotoxicity assays. The compound's estrogen-like activity suggests that potential hormonal effects should be carefully monitored.
|
| References |
|
| Additional Infomation |
It was isolated from Vaccaria segetalis; the structure is described in the original source.
Segetalin B is a cyclic pentapeptide extracted from Vaccaria segetalis (Wangbuliuxing), a plant used in traditional Chinese medicine. The compound possesses estrogen-like activity and has been reported to have anti-inflammatory, antioxidant, and potential neuroactive effects. Segetalin B's compact cyclic structure contributes to enhanced stability and resistance to enzymatic degradation, making it a useful molecule in natural product and peptide research. The compound is not approved as a drug and is intended for laboratory research purposes only. Its primary applications are in natural product research, peptide chemistry, and the study of phytoestrogens and their biological activities. |
| Molecular Formula |
C24H32N6O5
|
|---|---|
| Molecular Weight |
484.5481
|
| Exact Mass |
484.243
|
| Elemental Analysis |
C, 59.49; H, 6.66; N, 17.34; O, 16.51
|
| CAS # |
164991-89-3
|
| PubChem CID |
10345235
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
999.4±65.0 °C at 760 mmHg
|
| Flash Point |
558.2±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.535
|
| LogP |
-0.44
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
35
|
| Complexity |
833
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O=C1[C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C(C([H])([H])N([H])C([C@]([H])(C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C2=C([H])N([H])C3=C([H])C([H])=C([H])C([H])=C23)N([H])C([C@]([H])(C([H])([H])[H])N1[H])=O)=O)=O)=O
|
| InChi Key |
VBQDUSUKSGAFMN-OACKDKIBSA-N
|
| InChi Code |
InChI=1S/C24H32N6O5/c1-12(2)20-24(35)28-14(4)22(33)29-18(9-15-10-25-17-8-6-5-7-16(15)17)23(34)27-13(3)21(32)26-11-19(31)30-20/h5-8,10,12-14,18,20,25H,9,11H2,1-4H3,(H,26,32)(H,27,34)(H,28,35)(H,29,33)(H,30,31)/t13-,14-,18-,20-/m0/s1
|
| Chemical Name |
(3S,6S,9S,12S)-6-(1H-indol-3-ylmethyl)-3,9-dimethyl-12-propan-2-yl-1,4,7,10,13-pentazacyclopentadecane-2,5,8,11,14-pentone
|
| Synonyms |
Segetalin B; Vaccarin A, Segetalin B, Segetaline B; Cyclo(L-alanylglycyl-L-valyl-L-alanyl-L-tryptophyl)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~515.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0638 mL | 10.3189 mL | 20.6377 mL | |
| 5 mM | 0.4128 mL | 2.0638 mL | 4.1275 mL | |
| 10 mM | 0.2064 mL | 1.0319 mL | 2.0638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
